


## Antiparasitic agent-9

Cat. No.:	HY-151133
CAS No.:	2516237-50-4
Molecular Formula:	C <sub>18</sub> H <sub>20</sub> N <sub>6</sub> O <sub>2</sub> S
Molecular Weight:	384.46
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Antiparasitic agent-9 (compound 47) is an orally active and potent antiparasitic agent. Antiparasitic agent-9 shows antiparasitic activity against the human parasite <sup>[1]</sup> .																																						
<b>IC<sub>50</sub> &amp; Target</b>	Mite																																						
<b>In Vivo</b>	<p>Antiparasitic agent-9 (compound 47) (15 mg/kg, Orally, twice each day for 7 days) reduces adult worm burden in the jird <i>L. sigmodontis</i> infection model<sup>[1]</sup>.</p> <p>Antiparasitic agent-9 (2 mg/kg (IV), 10 and 30 mg/kg (PO); once) shows a brain to plasma ratio of 0.08, suggesting limited brain exposure<sup>[1]</sup>.</p> <p>Pharmacokinetic Parameters of Antiparasitic agent-9 in male Male CD-1 mouse<sup>[1]</sup>.</p> <table border="1"> <thead> <tr> <th></th> <th>PO (30 mg/kg)</th> <th>PO (10 mg/kg)</th> <th>IV (2 mg/kg)</th> </tr> </thead> <tbody> <tr> <td>C<sub>max</sub> (μM)</td> <td>13.9</td> <td>5.27 ± 0.83</td> <td></td> </tr> <tr> <td>T<sub>max</sub> (h)</td> <td>0.50</td> <td>4.0 ± 2.8</td> <td></td> </tr> <tr> <td>AUC<sub>0-inf</sub> (μM·h)</td> <td>121</td> <td>68.1±NC</td> <td></td> </tr> <tr> <td>CL (mL/min/kg)</td> <td></td> <td></td> <td>3.6 ± 0.22</td> </tr> <tr> <td>Vd ss (mL/kg)</td> <td></td> <td></td> <td>0.74 ± 0.08</td> </tr> <tr> <td>F (%)</td> <td></td> <td>57</td> <td></td> </tr> <tr> <td>brain/plasma [b]/[p]</td> <td>0.08</td> <td></td> <td></td> </tr> <tr> <td>efflux ratio (ER)</td> <td>12</td> <td></td> <td></td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>				PO (30 mg/kg)	PO (10 mg/kg)	IV (2 mg/kg)	C <sub>max</sub> (μM)	13.9	5.27 ± 0.83		T <sub>max</sub> (h)	0.50	4.0 ± 2.8		AUC <sub>0-inf</sub> (μM·h)	121	68.1±NC		CL (mL/min/kg)			3.6 ± 0.22	Vd ss (mL/kg)			0.74 ± 0.08	F (%)		57		brain/plasma [b]/[p]	0.08			efflux ratio (ER)	12		
	PO (30 mg/kg)	PO (10 mg/kg)	IV (2 mg/kg)																																				
C <sub>max</sub> (μM)	13.9	5.27 ± 0.83																																					
T <sub>max</sub> (h)	0.50	4.0 ± 2.8																																					
AUC <sub>0-inf</sub> (μM·h)	121	68.1±NC																																					
CL (mL/min/kg)			3.6 ± 0.22																																				
Vd ss (mL/kg)			0.74 ± 0.08																																				
F (%)		57																																					
brain/plasma [b]/[p]	0.08																																						
efflux ratio (ER)	12																																						

Animal Model:	Female BALB/c mice (infected with <i>L. sigmodontis</i> , 6-8 weeks) <sup>[1]</sup>
Dosage:	15 mg/kg
Administration:	Orally, twice each day for 7 days
Result:	Showed a significant worm burden reduction of 59% at 15 mg/kg.
Animal Model:	Male CD-1 mouse (n = 4) <sup>[1]</sup>
Dosage:	2 mg/kg (IV), 10 and 30 mg/kg (PO)
Administration:	IV, PO, once (Pharmacokinetic Analysis)
Result:	Showed a brain to plasma ratio of 0.08, suggesting limited brain exposure.

## REFERENCES

[1]. Hawryluk N, et al. Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrophilicidal Compounds for the Treatment of Human Filarial Infections. *J Med Chem*. 2022 Aug 16.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA